Sandoz’s Bourdage Makes Case For Tailored Biosimilar Pathways
Current Approach Of Phase III Studies ‘Is No Longer Justified In Many Cases’
A strong case exists for a more tailored approach to biosimilars development that could increase regulatory efficiency and broaden access, Sandoz’s head of biopharmaceuticals, Pierre Bourdage, tells Generics Bulletin in an exclusive interview.
